Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NervGen Pharma ( (NGEN) ) has shared an update.
NervGen Pharma Corp., a clinical-stage biopharmaceutical company listed on Nasdaq and specializing in neuroreparative therapies for spinal cord injury and other neurologic conditions, is advancing its lead drug candidate NVG-291, which has received both FDA Fast Track and EMA Orphan Drug designations. The company’s strategy centers on changing the treatment paradigm for chronic tetraplegia and broader nervous system damage using pharmacologic approaches.
On April 27, 2026, NervGen appointed Keith Vendola, MD, MBA, as Chief Financial Officer, tasking him with leading financial strategy, capital markets activities, and corporate development as the company prepares for its RESTORE registrational study in chronic tetraplegia. At the April 23, 2026 annual meeting, shareholders approved amendments to the company’s Articles and adopted a new 2026 Equity Incentive Plan under which Vendola received stock options, moves that collectively strengthen NervGen’s leadership bench, align management incentives, and support its next phase of clinical and corporate growth.
The most recent analyst rating on (NGEN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the NGEN Stock Forecast page.
More about NervGen Pharma
NervGen Pharma Corp. is a Vancouver-based, clinical-stage biopharmaceutical company focused on first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. Its lead candidate, NVG-291, a subcutaneous peptide targeting the CSPG-PTPσ pathway, has Fast Track status from the FDA and Orphan Drug designation from the EMA for spinal cord injury.
The company aims to transform outcomes in chronic tetraplegia and related nervous system damage through NVG-291 and its next-generation candidate, NVG-300. NervGen is listed on Nasdaq under the ticker NGEN and targets patients with significant unmet medical needs in neurotrauma and neurology.
Average Trading Volume: 158,541
Technical Sentiment Signal: Buy
Current Market Cap: $317.2M
For a thorough assessment of NGEN stock, go to TipRanks’ Stock Analysis page.